Published in J Virol on March 12, 2008
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Targeting of tetraspanin proteins--potential benefits and strategies. Nat Rev Drug Discov (2008) 1.91
The cell biology of receptor-mediated virus entry. J Cell Biol (2011) 1.75
Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol (2015) 1.67
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
Hepatitis C virus host cell entry. Curr Opin Virol (2012) 1.41
Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts. J Virol (2009) 1.19
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology (2009) 1.17
Tight junctions in the testis: new perspectives. Philos Trans R Soc Lond B Biol Sci (2010) 1.16
Hepatitis C virus: virology and life cycle. Clin Mol Hepatol (2013) 1.15
Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol (2012) 1.14
Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J Virol (2008) 1.12
The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses (2011) 1.07
Species-specific regions of occludin required by hepatitis C virus for cell entry. J Virol (2010) 1.07
Hepatocyte polarity. Compr Physiol (2013) 1.06
Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood (2008) 1.05
Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J Virol (2009) 1.04
A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One (2013) 1.04
Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem (2011) 1.04
Primary hepatocytes as targets for hepatitis C virus replication. J Viral Hepat (2008) 1.03
Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem (2012) 1.03
Hepatitis C Virus entry: the early steps in the viral replication cycle. Virol J (2009) 1.01
CD81 regulates cell migration through its association with Rac GTPase. Mol Biol Cell (2012) 0.94
Interacting regions of CD81 and two of its partners, EWI-2 and EWI-2wint, and their effect on hepatitis C virus infection. J Biol Chem (2011) 0.92
The second extracellular loop dictates Occludin-mediated HCV entry. Virology (2010) 0.92
Hepatitis C virus life cycle and lipid metabolism. Biology (Basel) (2014) 0.91
Hepatoma polarization limits CD81 and hepatitis C virus dynamics. Cell Microbiol (2012) 0.90
Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. J Virol (2013) 0.89
The SR-BI partner PDZK1 facilitates hepatitis C virus entry. PLoS Pathog (2010) 0.89
Mechanisms of viral entry: sneaking in the front door. Protoplasma (2010) 0.88
Lymphotropic HCV strain can infect human primary naïve CD4+ cells and affect their proliferation and IFN-γ secretion activity. J Gastroenterol (2010) 0.87
Targeting HCV entry for development of therapeutics. Viruses (2010) 0.86
Cell-cell contact-mediated hepatitis C virus (HCV) transfer, productive infection, and replication and their requirement for HCV receptors. J Virol (2013) 0.85
How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol (2014) 0.85
In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface. Cell Microbiol (2012) 0.85
Entry inhibitors: New advances in HCV treatment. Emerg Microbes Infect (2016) 0.84
CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84
Hijacking the endocytic machinery by microbial pathogens. Protoplasma (2010) 0.84
New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol (2013) 0.83
CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. Viruses (2014) 0.83
Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture. PLoS One (2012) 0.83
Chronic hepatitis C virus infection and lipoprotein metabolism. World J Gastroenterol (2015) 0.81
Autophagy in hepatitis C virus-host interactions: potential roles and therapeutic targets for liver-associated diseases. World J Gastroenterol (2014) 0.80
Role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function. J Virol (2012) 0.80
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A. J Virol (2015) 0.80
Novel full-spectral flow cytometry with multiple spectrally-adjacent fluorescent proteins and fluorochromes and visualization of in vivo cellular movement. Cytometry A (2015) 0.79
Systems Proteomics View of the Endogenous Human Claudin Protein Family. J Proteome Res (2016) 0.79
Distinct regions of the large extracellular domain of tetraspanin CD9 are involved in the control of human multinucleated giant cell formation. PLoS One (2014) 0.78
Production, purification and characterization of recombinant, full-length human claudin-1. PLoS One (2013) 0.78
Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry. World J Gastroenterol (2011) 0.78
Super-resolution microscopy: a virus' eye view of the cell. Viruses (2014) 0.78
A role for CD81 and hepatitis C virus in hepatoma mobility. Viruses (2014) 0.78
Viral kinetics suggests a reconciliation of the disparate observations of the modulation of claudin-1 expression on cells exposed to hepatitis C virus. PLoS One (2012) 0.78
Expression of tight junction protein claudin-1 in human crescentic glomerulonephritis. Int J Nephrol (2014) 0.77
Active RNA replication of hepatitis C virus downregulates CD81 expression. PLoS One (2013) 0.77
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. PLoS One (2015) 0.77
Claudins 1, 2, 3, 4, 5 and 7 in solar keratosis and squamocellular carcinoma of the skin. Int J Clin Exp Pathol (2013) 0.76
The missing pieces of the HCV entry puzzle. Future Virol (2015) 0.76
Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World J Gastroenterol (2014) 0.76
Regulation of FAK Activity by Tetraspan Proteins: Potential Clinical Implications in Cancer. Crit Rev Oncog (2015) 0.75
Attachment and Post-Attachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission. J Virol (2017) 0.75
Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display. Antimicrob Agents Chemother (2010) 0.75
Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus. World J Hepatol (2015) 0.75
Viruses and tetraspanins: lessons from single molecule approaches. Viruses (2014) 0.75
Claudins in viral infection: from entry to spread. Pflugers Arch (2016) 0.75
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 14.41
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol (1998) 7.78
Quantitative fluorescence resonance energy transfer measurements using fluorescence microscopy. Biophys J (1998) 6.27
Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A (2002) 5.02
Claudins and epithelial paracellular transport. Annu Rev Physiol (2006) 4.79
Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell (2006) 4.68
A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J Cell Biol (1998) 4.64
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 4.58
Junction adhesion molecule is a receptor for reovirus. Cell (2001) 4.00
Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol (2003) 3.90
FRET or no FRET: a quantitative comparison. Biophys J (2003) 3.88
Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A (1994) 3.76
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
The Los Alamos hepatitis C sequence database. Bioinformatics (2004) 3.67
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Photobleaching-corrected FRET efficiency imaging of live cells. Biophys J (2004) 3.41
The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol (2005) 3.35
Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci (2001) 3.20
CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A (2004) 3.01
Structure and function of claudins. Biochim Biophys Acta (2007) 2.98
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest (2001) 2.85
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol (2006) 2.74
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Fluorescence resonance energy transfer (FRET) microscopy imaging of live cell protein localizations. J Cell Biol (2003) 2.55
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
Formation of tight junction: determinants of homophilic interaction between classic claudins. FASEB J (2007) 2.43
Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett (2003) 2.41
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem (2005) 2.31
Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol (1999) 2.26
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
Measurement of FRET efficiency and ratio of donor to acceptor concentration in living cells. Biophys J (2006) 2.23
Detecting microdomains in intact cell membranes. Annu Rev Phys Chem (2005) 2.22
Kinesin-1 structural organization and conformational changes revealed by FRET stoichiometry in live cells. J Cell Biol (2007) 2.08
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
CAR: a virus receptor within the tight junction. Adv Drug Deliv Rev (2005) 1.98
Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol (2006) 1.96
Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J Virol (2007) 1.95
Hepatitis C virus entry. J Biol Chem (2007) 1.91
CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs. EMBO J (2001) 1.90
Tetraspanins: molecular organisers of the leukocyte surface. Trends Immunol (2003) 1.79
The major CD9 and CD81 molecular partner. Identification and characterization of the complexes. J Biol Chem (2001) 1.74
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
EWI-2 is a major CD9 and CD81 partner and member of a novel Ig protein subfamily. J Biol Chem (2001) 1.72
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Imaging kinase--AKAP79--phosphatase scaffold complexes at the plasma membrane in living cells using FRET microscopy. J Cell Biol (2002) 1.67
Large movement in the C terminus of CLC-0 chloride channel during slow gating. Nat Struct Mol Biol (2006) 1.62
Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol (2007) 1.59
GFP imaging: methodology and application to investigate cellular compartmentation in plants. J Exp Bot (2001) 1.58
Profiling of the tetraspanin web of human colon cancer cells. Mol Cell Proteomics (2006) 1.53
Fluorescence resonance energy transfer (FRET) measurement by gradual acceptor photobleaching. J Microsc (2005) 1.51
EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells. Biochem J (2003) 1.50
Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J Biol Chem (2008) 1.49
Regulation of heterotypic claudin compatibility. J Biol Chem (2007) 1.48
FPRP, a major, highly stoichiometric, highly specific CD81- and CD9-associated protein. J Biol Chem (2000) 1.47
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
Dynamic regulation of a GPCR-tetraspanin-G protein complex on intact cells: central role of CD81 in facilitating GPR56-Galpha q/11 association. Mol Biol Cell (2004) 1.36
The roles of claudin superfamily proteins in paracellular transport. Traffic (2001) 1.34
A novel cysteine cross-linking method reveals a direct association between claudin-1 and tetraspanin CD9. Mol Cell Proteomics (2007) 1.30
Junctional adhesion molecule 1 is a functional receptor for feline calicivirus. J Virol (2006) 1.24
Regulation of CXCR4 receptor dimerization by the chemokine SDF-1alpha and the HIV-1 coat protein gp120: a fluorescence resonance energy transfer (FRET) study. J Pharmacol Exp Ther (2004) 1.21
The maintenance and generation of membrane polarity in hepatocytes. Hepatology (2004) 1.14
FRET and colocalization analyzer--a method to validate measurements of sensitized emission FRET acquired by confocal microscopy and available as an ImageJ Plug-in. Microsc Res Tech (2006) 1.04
Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br J Haematol (2002) 1.04
HIV gp120-induced interaction between CD4 and CCR5 requires cholesterol-rich microenvironments revealed by live cell fluorescence resonance energy transfer imaging. J Biol Chem (2006) 1.01
Tight junction proteins ZO-1, occludin, and claudins in developing and adult human perineurium. J Histochem Cytochem (2004) 0.96
Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol (2007) 0.95
CD4 interacts constitutively with multiple CCR5 at the plasma membrane of living cells. A fluorescence recovery after photobleaching at variable radii approach. J Biol Chem (2007) 0.91
CD4 and CCR5 constitutively interact at the plasma membrane of living cells: a confocal fluorescence resonance energy transfer-based approach. J Biol Chem (2006) 0.88
An ultrastructural study of microvascular inter-endothelial tight junctions in normal endometrium. Micron (2006) 0.78
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol (2006) 2.77
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med (2011) 2.47
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation (2007) 2.40
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS (2006) 2.23
Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis. Hepatology (2004) 2.17
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
Processed residual pump blood in cardiac surgery: the Processed Residual Blood in Cardiac surgery trial. Transfusion (2012) 2.02
Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway. Oncogene (2003) 1.98
Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J Virol (2007) 1.95
CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol (2012) 1.95
Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76
Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol (2004) 1.76
Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71
Organellar dynamics during the cell cycle of Toxoplasma gondii. J Cell Sci (2008) 1.70
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Golgi biogenesis in Toxoplasma gondii. Nature (2002) 1.67
Inferring viral quasispecies spectra from 454 pyrosequencing reads. BMC Bioinformatics (2011) 1.62
Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol (2010) 1.61
Paranuclear dot-like immunostaining for CD99: a unique staining pattern for diagnosing solid-pseudopapillary neoplasm of the pancreas. Am J Surg Pathol (2011) 1.58
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Phylogeny of the SARS coronavirus. Science (2003) 1.56
Measuring tubulin content in Toxoplasma gondii: a comparison of laser-scanning confocal and wide-field fluorescence microscopy. Proc Natl Acad Sci U S A (2002) 1.55
Development of the antibody response in acute HIV-1 infection. AIDS (2004) 1.54
Differentiation between benign and malignant solid pseudopapillary tumor of the pancreas by MDCT. Eur J Radiol (2012) 1.49
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology (2012) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Isolation of primary human hepatocytes from normal and diseased liver tissue: a one hundred liver experience. PLoS One (2011) 1.34
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood (2007) 1.32
The study molecular epidemiology of canine parvovirus, Europe. Emerg Infect Dis (2007) 1.31
Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis (2008) 1.30
Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol (2008) 1.29
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28
Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine (2007) 1.28